This story is part of the Pink Sheet’s coverage of the selection of the first 10 drugs for Medicare price negotiation.
Bristol Myers Squibb/Pfizer
Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List
The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.
